TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck

OBJECTIVES: The aim of this study was to confirm the efficacy of the ERBITAX scheme (paclitaxel 80 mg/m(2) weekly and cetuximab 400 mg/m(2) loading dose, and then 250 mg/m(2) weekly) as first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) w...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubió-Casadevall, Jordi, Cirauqui Cirauqui, Beatriz, Martinez Trufero, Javier, Plana Serrahima, Maria, García Castaño, Almudena, Carral Maseda, Alberto, Iglesias Docampo, Lara, Pérez Segura, Pedro, Ceballos Lenza, Isaac, Gutiérrez Calderón, Vanesa, Fuster Salvà, José, Pena Álvarez, Carolina, Hernandez, Irene, del Barco Morillo, Edel, Chaves Conde, Manuel, Martínez Galán, Joaquina, Durán Sánchez, Marisa, Quiroga, Vanesa, Ortega, Eugenia, Mesia, Ricard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432957/
https://www.ncbi.nlm.nih.gov/pubmed/37601652
http://dx.doi.org/10.3389/fonc.2023.1226939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432957/
https://www.ncbi.nlm.nih.gov/pubmed/37601652
http://dx.doi.org/10.3389/fonc.2023.1226939

Ejemplares similares